major breakthrough is on the horizon for Crohn's disease

    A major breakthrough is on the horizon for Crohn's disease.

    A new biotech drug is expected next year...called Avakine (infliximab) by Centocor.

    Avakine is a monoclonal antibody that blocks tumor necrosis factor...and therefore, slows inflammation.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote